Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Rating)’s share price reached a new 52-week low during mid-day trading on Friday after Credit Suisse Group lowered their price target on the stock from $40.00 to $38.00. Credit Suisse Group currently has an outperform rating on the stock. Mineralys Therapeutics traded as low as $15.04 and last traded at $15.20, with a volume of 25683 shares trading hands. The stock had previously closed at $15.38.
MLYS has been the topic of several other reports. Wells Fargo & Company began coverage on shares of Mineralys Therapeutics in a research note on Tuesday, March 7th. They set an “overweight” rating and a $27.00 target price on the stock. Stifel Nicolaus began coverage on shares of Mineralys Therapeutics in a research note on Tuesday, March 7th. They set a “buy” rating and a $45.00 target price on the stock. Guggenheim began coverage on shares of Mineralys Therapeutics in a research report on Tuesday, March 7th. They issued a “buy” rating and a $32.00 price objective on the stock. Bank of America began coverage on shares of Mineralys Therapeutics in a research report on Tuesday, March 7th. They issued a “buy” rating and a $39.00 price objective on the stock. Finally, Evercore ISI began coverage on shares of Mineralys Therapeutics in a research report on Tuesday, March 7th. They issued an “outperform” rating on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Mineralys Therapeutics presently has an average rating of “Buy” and an average target price of $36.20.
Insider Buying and Selling at Mineralys Therapeutics
In other Mineralys Therapeutics news, CFO Adam Scott Levy bought 6,250 shares of the company’s stock in a transaction on Tuesday, February 14th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $100,000.00. Following the acquisition, the chief financial officer now owns 350,811 shares of the company’s stock, valued at approximately $5,612,976. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Ra Capital Management, L.P. purchased 1,250,000 shares of the firm’s stock in a transaction on Tuesday, February 14th. The shares were bought at an average cost of $16.00 per share, with a total value of $20,000,000.00. Following the purchase, the director now directly owns 1,867,229 shares of the company’s stock, valued at $29,875,664. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Adam Scott Levy purchased 6,250 shares of the firm’s stock in a transaction on Tuesday, February 14th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $100,000.00. Following the completion of the purchase, the chief financial officer now directly owns 350,811 shares in the company, valued at $5,612,976. The disclosure for this purchase can be found here. In the last three months, insiders acquired 1,568,750 shares of company stock worth $25,100,000.
About Mineralys Therapeutics
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc is based in RADNOR, Pa.